Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023–2024

Abstract

Background: The National Advisory Committee on Immunization (NACI) reviews the evolving evidence on influenza immunization and provides annual recommendations regarding the use of seasonal influenza vaccines. The NACI Statement on Seasonal Influenza Vaccine for 2023–2024 updates the 2022–2023 NACI recommendations. Objective: To summarize the 2023–2024 NACI seasonal influenza vaccine recommendations and to highlight new and updated information. Methods: In the preparation of the Statement on Seasonal Influenza Vaccine for 2023–2024 , the NACI Influenza Working Group applied the NACI evidence-based process to critically appraise the available evidence and to propose recommendations. The recommendations were then considered and approved by NACI in light of the available evidence. Results: Key changes for the 2023–2024 season include: 1) incorporation of updated information/guidance on influenza vaccination in the context of the coronavirus disease 2019 (COVID-19); 2) new recommendations for Flucelvax ® Quad and Influvac ® Tetra, the two quadrivalent inactivated influenza vaccines with expanded paediatric age indications; and 3) an update to the format of the Statement. Conclusion: Overall, NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually to all individuals aged six months and older who do not have a contraindication to the vaccine, with particular focus on the groups for whom influenza vaccination is particularly recommended.